DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extensionWilliam J. Sandborn, Silvio Danese, David Rowbotham et al.|Journal of Crohn s and Colitis|2020Cited by 3
P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extensionSilvio Danese, Bruce E. Sands, Remo Panaccione et al.|Journal of Crohn s and Colitis|2020Cited by 3
Tu1885 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN BIOLOGIC NAÏVE, BIOLOGIC NON-FAILURE, AND BIOLOGIC FAILURE POPULATIONS THROUGH 2 YEARS: UNIFI LONG-TERM EXTENSIONBruce E. Sands, Colleen Marano, Yiying Zhou et al.|Gastroenterology|2020Cited by 2
P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extensionB E Sands, Laurent Peyrin‐Biroulet, María T. Abreu et al.|Journal of Crohn s and Colitis|2020Cited by 2
Tu1848 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 2 YEARS: RESULTS OF THE UNIFI MAINTENANCE STUDY AND LONGTERM EXTENSIONWilliam J. Sandborn, Silvio Danese, Bruce E. Sands et al.|Gastroenterology|2020Cited by 2